2006 | Phase II Study of Cisplatin Combined with Weekly Gemcitabine in the Treatment of Patients with Metastatic Pancreatic Carcinoma | PANCREATOLOGY |
2012 | Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer | ANTICANCER RESEARCH |
2008 | Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer
| ANNALS OF ONCOLOGY |
2021 | Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
2023 | Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
2022 | Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer | INTERNATIONAL JOURNAL OF CANCER |
2007 | Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib | JOURNAL OF CLINICAL ONCOLOGY |
2006 | Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
2015 | Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10 | GYNECOLOGIC ONCOLOGY |
2003 | Phase II Study of Gemcitabine and Vinorelbine as Second-Line Chemotherapy in Non-Small Cell Lung Cancer
| CANCER RESEARCH AND TREATMENT |
2022 | Phase II study of gemcitabine with oxaliplatin (GEMOX) in heavily treated patients with advanced hepatocellular carcinoma after failure of sorafenib treatment (PEACH) | JOURNAL OF CLINICAL ONCOLOGY |
2022 | Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer | ANNALS OF ONCOLOGY |
2010 | Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer | RADIOTHERAPY AND ONCOLOGY |
2022 | Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progress | JOURNAL OF CLINICAL ONCOLOGY |
2011 | Phase II study of sunitinib as second-line treatment for advanced gastric cancer
| INVESTIGATIONAL NEW DRUGS |
2012 | Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma | JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
2009 | Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma | ONCOLOGY |
2015 | Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
2012 | Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
2022 | Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B) | BREAST |